Reversible sensorineural hearing loss after renal transplant immunosuppression with OKT3 (muromonab-CD3)

Alan F. Cohen, Christopher J. Hartnick, Richard V. Smith

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Reversible and irreversible ototoxicity has been documented following the administration of various therapeutic agents. Reversible hearing loss is a known complication folio wing the administration of quinine, salicylates and other nonsteroidal anti-inflammatory drugs, and erythromycin. We report a case of reversible hearing loss following OKT3 (murine monoclonal antibody CD3) administration. OKT3, a monoclonal antibody used as an immunosuppressant following cadaveric renal transplants, was associated with a transient sensorineural hearing loss that reversed following discontinuation of OKT3.

Original languageEnglish (US)
Pages (from-to)640-642
Number of pages3
JournalAnnals of Otology, Rhinology and Laryngology
Volume106
Issue number8
StatePublished - 1997

Fingerprint

Muromonab-CD3
Sensorineural Hearing Loss
Immunosuppression
Transplants
Kidney
Hearing Loss
Quinine
Salicylates
Erythromycin
Immunosuppressive Agents
Anti-Inflammatory Agents
Pharmaceutical Preparations
Therapeutics

Keywords

  • Immunosuppression
  • OKT3
  • Sensorineural hearing loss
  • Transplant

ASJC Scopus subject areas

  • Otorhinolaryngology

Cite this

Reversible sensorineural hearing loss after renal transplant immunosuppression with OKT3 (muromonab-CD3). / Cohen, Alan F.; Hartnick, Christopher J.; Smith, Richard V.

In: Annals of Otology, Rhinology and Laryngology, Vol. 106, No. 8, 1997, p. 640-642.

Research output: Contribution to journalArticle

@article{d594d609bc5147aaaf71e24dbb6ba7a9,
title = "Reversible sensorineural hearing loss after renal transplant immunosuppression with OKT3 (muromonab-CD3)",
abstract = "Reversible and irreversible ototoxicity has been documented following the administration of various therapeutic agents. Reversible hearing loss is a known complication folio wing the administration of quinine, salicylates and other nonsteroidal anti-inflammatory drugs, and erythromycin. We report a case of reversible hearing loss following OKT3 (murine monoclonal antibody CD3) administration. OKT3, a monoclonal antibody used as an immunosuppressant following cadaveric renal transplants, was associated with a transient sensorineural hearing loss that reversed following discontinuation of OKT3.",
keywords = "Immunosuppression, OKT3, Sensorineural hearing loss, Transplant",
author = "Cohen, {Alan F.} and Hartnick, {Christopher J.} and Smith, {Richard V.}",
year = "1997",
language = "English (US)",
volume = "106",
pages = "640--642",
journal = "Annals of Otology, Rhinology and Laryngology",
issn = "0003-4894",
publisher = "Annals Publishing Company",
number = "8",

}

TY - JOUR

T1 - Reversible sensorineural hearing loss after renal transplant immunosuppression with OKT3 (muromonab-CD3)

AU - Cohen, Alan F.

AU - Hartnick, Christopher J.

AU - Smith, Richard V.

PY - 1997

Y1 - 1997

N2 - Reversible and irreversible ototoxicity has been documented following the administration of various therapeutic agents. Reversible hearing loss is a known complication folio wing the administration of quinine, salicylates and other nonsteroidal anti-inflammatory drugs, and erythromycin. We report a case of reversible hearing loss following OKT3 (murine monoclonal antibody CD3) administration. OKT3, a monoclonal antibody used as an immunosuppressant following cadaveric renal transplants, was associated with a transient sensorineural hearing loss that reversed following discontinuation of OKT3.

AB - Reversible and irreversible ototoxicity has been documented following the administration of various therapeutic agents. Reversible hearing loss is a known complication folio wing the administration of quinine, salicylates and other nonsteroidal anti-inflammatory drugs, and erythromycin. We report a case of reversible hearing loss following OKT3 (murine monoclonal antibody CD3) administration. OKT3, a monoclonal antibody used as an immunosuppressant following cadaveric renal transplants, was associated with a transient sensorineural hearing loss that reversed following discontinuation of OKT3.

KW - Immunosuppression

KW - OKT3

KW - Sensorineural hearing loss

KW - Transplant

UR - http://www.scopus.com/inward/record.url?scp=8544245667&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=8544245667&partnerID=8YFLogxK

M3 - Article

C2 - 9270425

AN - SCOPUS:8544245667

VL - 106

SP - 640

EP - 642

JO - Annals of Otology, Rhinology and Laryngology

JF - Annals of Otology, Rhinology and Laryngology

SN - 0003-4894

IS - 8

ER -